Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
- Journal Article
Rights / licenseCreative Commons Attribution 4.0 International
Background Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responder population that benefits from treatment. Methods A novel statistical method based on the Indian buffet process (IBP) was used to identify biomarkers predictive of response to treatment with Codrituzumab. The IBP is a novel method that allows flexibility in analysis design, and which is sensitive to slight, but meaningful between-group differences in biomarkers in very complex datasets Results The IBP model identified several subpopulations of patients having defined biomarker values. Tumor necrosis and viable cell content in the tumor were identified as prognostic markers of disease progression, as were the well-known HCC prognostic markers of disease progression, alpha-fetoprotein and Glypican-3 expression. Predictive markers of treatment response included natural killer (NK) cell surface markers and parameters influencing NK cell activity, all related to the mechanism of action of this drug Conclusions The Indian buffet process can be effectively used to detect statistically significant signals with high sensitivity in complex and noisy biological data Show more
Journal / seriesBMC Cancer
Pages / Article No.
SubjectCodrituzumab; Indian buffet process; Natural killer cells
MoreShow all metadata